Company Profile
Solid Biosciences Stock Price, News & Analysis
- Ticker:
- SLDB
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
8.71 USD (-0.23%)
Close
Last updated: August 6, 2026
648M USD
Market cap
Why the stock is moving
The latest monitored company update is “Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates.” The corresponding closing-price reaction is not yet available.
Company overview
Neuromuscular Gene Therapy Company
Solid Biosciences develops adeno-associated virus gene therapies for neuromuscular and cardiac diseases.
SGT-003
SGT-003 combines a microdystrophin construct with the POLARIS-101 capsid, designed to improve skeletal and cardiac muscle delivery while reducing liver targeting in Duchenne muscular dystrophy.
Cardiac Gene Therapy Pipeline
Additional programs include SGT-212 for Friedreich’s ataxia and SGT-501 for catecholaminergic polymorphic ventricular tachycardia.
Future catalysts
Solid expects to dose the first participant in the Phase 1b ARTEMIS study of SGT-501 in the second half of 2026.
The Phase 3 IMPACT DUCHENNE study of SGT-003 is underway, with future enrollment and data supporting the global registration program.
Recent news
- 01
Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
Source: Solid Biosciences
- 02
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Solid Biosciences
- 03
Solid Biosciences to Participate at Upcoming Investor Conferences
Source: Solid Biosciences
- 04
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
Source: Solid Biosciences
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Solid Biosciences (SLDB)?
Solid Biosciences (SLDB) most recently closed at 8.71 USD, a -0.23% move versus the previous session.
What is the market cap of Solid Biosciences (SLDB)?
Solid Biosciences currently has a market capitalization of 648M USD on BioPharmSignal.
What does Solid Biosciences do?
Neuromuscular Gene Therapy Company Solid Biosciences develops adeno-associated virus gene therapies for neuromuscular and cardiac diseases. SGT-003 SGT-003 combines a microdystrophin construct with the POLARIS-101 capsid, designed to improve skeletal and cardiac muscle delivery while reducing liver targeting in Duchenne muscular dystrophy. Cardiac Gene...
On which exchange is SLDB stock listed?
Solid Biosciences (SLDB) is associated with NASDAQ, United States, Biopharma.
What is SGT-003?
The Phase 3 IMPACT DUCHENNE study of SGT-003 is underway, with future enrollment and data supporting the global registration program.
Which conditions is Solid Biosciences targeting with SGT-003?
The Phase 3 IMPACT DUCHENNE study of SGT-003 is underway, with future enrollment and data supporting the global registration program.
How does Solid Biosciences describe recent progress with SGT-003?
The Phase 3 IMPACT DUCHENNE study of SGT-003 is underway, with future enrollment and data supporting the global registration program.
What is POLARIS-101?
SGT-003 SGT-003 combines a microdystrophin construct with the POLARIS-101 capsid, designed to improve skeletal and cardiac muscle delivery while reducing liver targeting in Duchenne muscular dystrophy.